Consultation response on fees to the Medical Products Agency

The Medical Products Agency is proposing an increase in many fees for the control of medicines. SwedenBIO emphasizes in the consultation response that LV should work more for cost savings and criticizes the proposed large increases in fees for clinical trials and type II amendments.